Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Terminated

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

Outcome
Stopped early. Results posted; single-arm, no comparisonAs of 31 JAN 2018, the study was terminated by the sponsor due to PK variability. (Business decision)
Phase
Phase 1 / Phase 2
Status
Terminated
Study type
Interventional
Start
14 April 2015
Ended
31 January 2018
Enrollment
69 participants
Sites
12
Primary outcomes
Number of Participants With a Treatment-emergent Adverse Event (TEAE)
Sponsor type
Industry
Results posted
14 June 2019
Last update
14 June 2019

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 14 June 2019
Primary outcome
Number of Participants With a Treatment-emergent Adverse Event (TEAE)Part 1 / Treatment Group A: 15 MG QD INCB054329: 4 of 4Part 1 / Treatment Group A: 22.5 MG QD INCB054329: 5 of 5Part 1 / Treatment Group A: 15 MG BID INCB054329: 6 of 6Part 1 / Treatment Group A: 30 MG QD INCB054329: 5 of 5Part 1 / Treatment Group A: 22.5 MG BID INCB054329: 3 of 3Part 1 / Treatment Group A: 22.5 MG BID 5/2 INCB054329: 4 of 4Part 1 / Treatment Group A: 22.5 MG BID 4/3 INCB054329: 4 of 4Part 1 / Treatment Group A: 22.5 MG BID 7/7 INCB054329: 3 of 3Values: ParticipantsTime frame: up to 30 daysNo analysis posted for this outcome (outcome 1)
Participants
Part 1 / Treatment Group A: 15 MG QD INCB054329: 4 started, 0 completedPart 1 / Treatment Group A: 22.5 MG QD INCB054329: 5 started, 0 completedPart 1 / Treatment Group A: 15 MG BID INCB054329: 6 started, 0 completedPart 1 / Treatment Group A: 30 MG QD INCB054329: 5 started, 0 completedPart 1 / Treatment Group A: 22.5 MG BID INCB054329: 3 started, 0 completedPart 1 / Treatment Group A: 22.5 MG BID 5/2 INCB054329: 4 started, 0 completedPart 1 / Treatment Group A: 22.5 MG BID 4/3 INCB054329: 4 started, 0 completedPart 1 / Treatment Group A: 22.5 MG BID 7/7 INCB054329: 3 started, 0 completedPart 1 / Treatment Group A: 20 MG BID INCB054329: 8 started, 0 completedPart 1 / Treatment Group A: 25 MG BID 5/2 INCB054329: 8 started, 0 completedPart 1 / Treatment Group A: 25 MG BID 7/7 INCB054329: 4 started, 0 completedPart 1 / Treatment Group B: 20 MG BID INCB054329: 4 started, 0 completedPart 2 / Treatment Group A: 20 MG BID INCB054329: 10 started, 0 completedPart 2 / Treatment Group C: 20 mg BID INCB054329: 1 started, 0 completed
Serious adverse events
Part 1 / Treatment Group A: 15 MG QD INCB054329: 1 of 4Part 1 / Treatment Group A: 22.5 MG QD INCB054329: 1 of 5Part 1 / Treatment Group A: 15 MG BID INCB054329: 1 of 6Part 1 / Treatment Group A: 30 MG QD INCB054329: 1 of 5Part 1 / Treatment Group A: 22.5 MG BID INCB054329: 3 of 3Part 1 / Treatment Group A: 22.5 MG BID 5/2 INCB054329: 3 of 4Part 1 / Treatment Group A: 22.5 MG BID 4/3 INCB054329: 1 of 4Part 1 / Treatment Group A: 22.5 MG BID 7/7 INCB054329: 1 of 3Part 1 / Treatment Group A: 20 MG BID INCB054329: 3 of 8Part 1 / Treatment Group A: 25 MG BID 5/2 INCB054329: 3 of 8Part 1 / Treatment Group A: 25 MG BID 7/7 INCB054329: 1 of 4Part 1 / Treatment Group B: 20 MG BID INCB054329: 3 of 4Part 2 / Treatment Group A: 20 MG BID INCB054329: 3 of 10Part 2 / Treatment Group C: 20 mg BID INCB054329: 1 of 1Participants with at least one serious adverse event, of those at risk, as posted
10 secondary outcomes, the first 8 shown
Maximum Plasma Concentration (Cmax) Analysis of INCB054329
INCB054329 Monotherapy - 15 mg QD 278 (82.6), n=4; INCB054329 Monotherapy - 15 mg BID 267 (201), n=5; INCB054329 Monotherapy - 22.5 mg QD 479 (154), n=4; INCB054329 Monotherapy - 30 mg QD 389 (393), n=4; INCB054329 Monotherapy - 20 mg BID 652 (348), n=14; INCB054329 Monotherapy - 22.5 mg BID 720 (472), n=12; INCB054329 Monotherapy - 25 mg BID 449 (335), n=8; INCB054329 Monotherapy - Overall Dosing… NA (NA), n=51 [mean nM, Standard Deviation]
Time to Maximum Plasma Concentration (Tmax) Analysis of INCB054329
INCB054329 Monotherapy - 15 mg QD 1.0 (0.52 to 1.0), n=4; INCB054329 Monotherapy - 15 mg BID 0.93 (0.5 to 1.1), n=5; INCB054329 Monotherapy - 22.5 mg QD 0.53 (0.5 to 1.0), n=4; INCB054329 Monotherapy - 30 mg QD 1.0 (0.52 to 1.0), n=4; INCB054329 Monotherapy - 20 mg BID 1.0 (0.48 to 2.0), n=14; INCB054329 Monotherapy - 22.5 mg BID 1.0 (0.5 to 4.1), n=12; INCB054329 Monotherapy - 25 mg BID 0.77 (0.50 to 2.2), n=8; INCB054329 Monotherapy - Overall Dosing… 1.0 (0.48 to 4.1), n=51 [median hour, Full Range]
Minimum Observed Plasma Concentration Over the Dose Interval (Cmin) Analysis of INCB054329
INCB054329 Monotherapy - 15 mg QD 0.538 (1.08), n=4; INCB054329 Monotherapy - 15 mg BID 1.09 (2.45), n=5; INCB054329 Monotherapy - 22.5 mg QD 0 (0), n=4; INCB054329 Monotherapy - 30 mg QD 1.51 (3.02), n=4; INCB054329 Monotherapy - 20 mg BID 54.2 (91.1), n=13; INCB054329 Monotherapy - 22.5 mg BID 14.6 (45), n=12; INCB054329 Monotherapy - 25 mg BID 0 (0), n=7; INCB054329 Monotherapy - Overall Dosing… NA (NA), n=49 [mean nM, Standard Deviation]
AUC0-t Analysis of INCB054329
INCB054329 Monotherapy - 15 mg QD 686 (178), n=4; INCB054329 Monotherapy - 15 mg BID 611 (628), n=5; INCB054329 Monotherapy - 22.5 mg QD 883 (409), n=4; INCB054329 Monotherapy - 30 mg QD 1150 (1660), n=4; INCB054329 Monotherapy - 20 mg BID 2130 (1690), n=14; INCB054329 Monotherapy - 22.5 mg BID 1970 (1560), n=12; INCB054329 Monotherapy - 25 mg BID 995 (843), n=8; INCB054329 Monotherapy - Overall Dosing… NA (NA), n=51 [mean nM*h, Standard Deviation]
Cl/F Analysis of INCB054329
INCB054329 Monotherapy - 15 mg QD 61.8 (21.3), n=4; INCB054329 Monotherapy - 15 mg BID 85.0 (42.9), n=4; INCB054329 Monotherapy - 22.5 mg BID 81.7 (29.4), n=4; INCB054329 Monotherapy - 30 mg QD 234 (184), n=4; INCB054329 Monotherapy - 20 mg BID 92.3 (201), n=14; INCB054329 Monotherapy - 22.5 mg QD 48.3 (33.7), n=11; INCB054329 Monotherapy - 25 mg BID 130 (127), n=7; INCB054329 Monotherapy - Overall Dosing… 95.5 (135), n=48 [mean L/h, Standard Deviation]
Pharmacodynamics (PD) Analysis - Total c-Myc % Inhibition Versus INCB054329
INCB054329 Monotherapy 283.4, n=49 [nM]
ORR · Objective Response Rate (ORR)
Complete response (CR): Part 2 / Treatment Group A: 20 MG BID I… 0/10 [Participants] (first of 6 rows)
PFS · Progression Free Survival (PFS)
Part 2 / Treatment Group A: 20 MG BID I… 2.04 (0.63 to 4.21), n=10 [median months, 95% Confidence Interval]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment groups also had an intra-patient dose titration (Part 2).

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Number of Participants With a Treatment-emergent Adverse Event (TEAE) [up to 30 days]. Count Of Participants, Participants. Part 1 / Treatment Group A: 15 MG QD INCB054329 (n=4): 4; Part 1 / Treatment Group A: 22.5 MG QD INCB054329 (n=5): 5; Part 1 / Treatment Group A: 15 MG BID INCB054329 (n=6): 6; Part 1 / Treatment Group A: 30 MG QD INCB054329 (n=5): 5; Part 1 / Treatment Group A: 22.5 MG BID INCB054329 (n=3): 3; Part 1 / Treatment Group A: 22.5 MG BID 5/2 INCB054329 (n=4): 4; Part 1 / Treatment Group A: 22.5 MG BID 4/3 INCB054329 (n=4): 4; Part 1 / Treatment Group A: 22.5 MG BID 7/7 INCB054329 (n=3): 3; Part 1 / Treatment Group A: 20 MG BID INCB054329 (n=8): 8; Part 1 / Treatment Group A: 25 MG BID 5/2 INCB054329 (n=8): 8; Part 1 / Treatment Group A: 25 MG BID 7/7 INCB054329 (n=4): 3; Part 1 / Treatment Group B: 20 MG BID INCB054329 (n=4): 4; Part 2 / Treatment Group A: 20 MG BID INCB054329 (n=10): 10; Part 2 / Treatment Group C: 20 mg BID INCB054329 (n=1): 1.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Maximum Plasma Concentration (Cmax) Analysis of INCB054329 [Summary of steady-state PK parameters by dosing regimen at Day 15]. Mean, nM (Standard Deviation). INCB054329 Monotherapy - 15 mg QD (n=4): 278 (82.6); INCB054329 Monotherapy - 15 mg BID (n=5): 267 (201); INCB054329 Monotherapy - 22.5 mg QD (n=4): 479 (154); INCB054329 Monotherapy - 30 mg QD (n=4): 389 (393); INCB054329 Monotherapy - 20 mg BID (n=14): 652 (348); INCB054329 Monotherapy - 22.5 mg BID (n=12): 720 (472); INCB054329 Monotherapy - 25 mg BID (n=8): 449 (335); INCB054329 Monotherapy - Overall Dosing Regimen (n=51): NA (NA) [Dose dependent parameter and overall summary not provided.].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Time to Maximum Plasma Concentration (Tmax) Analysis of INCB054329 [Summary of steady-state PK parameters by dosing regimen at Day 15]. Median, hour (Full Range). INCB054329 Monotherapy - 15 mg QD (n=4): 1.0 (0.52 to 1.0); INCB054329 Monotherapy - 15 mg BID (n=5): 0.93 (0.5 to 1.1); INCB054329 Monotherapy - 22.5 mg QD (n=4): 0.53 (0.5 to 1.0); INCB054329 Monotherapy - 30 mg QD (n=4): 1.0 (0.52 to 1.0); INCB054329 Monotherapy - 20 mg BID (n=14): 1.0 (0.48 to 2.0); INCB054329 Monotherapy - 22.5 mg BID (n=12): 1.0 (0.5 to 4.1); INCB054329 Monotherapy - 25 mg BID (n=8): 0.77 (0.50 to 2.2); INCB054329 Monotherapy - Overall Dosing Regimen (n=51): 1.0 (0.48 to 4.1).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Minimum Observed Plasma Concentration Over the Dose Interval (Cmin) Analysis of INCB054329 [Summary of steady-state PK parameters by dosing regimen at Day 15]. Mean, nM (Standard Deviation). INCB054329 Monotherapy - 15 mg QD (n=4): 0.538 (1.08); INCB054329 Monotherapy - 15 mg BID (n=5): 1.09 (2.45); INCB054329 Monotherapy - 22.5 mg QD (n=4): 0 (0); INCB054329 Monotherapy - 30 mg QD (n=4): 1.51 (3.02); INCB054329 Monotherapy - 20 mg BID (n=13): 54.2 (91.1); INCB054329 Monotherapy - 22.5 mg BID (n=12): 14.6 (45); INCB054329 Monotherapy - 25 mg BID (n=7): 0 (0); INCB054329 Monotherapy - Overall Dosing Regimen (n=49): NA (NA) [Dose dependent parameter and overall summary not provided.].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

AUC0-t Analysis of INCB054329 [Summary of steady-state PK parameters by dosing regimen at Day 15]. Mean, nM*h (Standard Deviation). INCB054329 Monotherapy - 15 mg QD (n=4): 686 (178); INCB054329 Monotherapy - 15 mg BID (n=5): 611 (628); INCB054329 Monotherapy - 22.5 mg QD (n=4): 883 (409); INCB054329 Monotherapy - 30 mg QD (n=4): 1150 (1660); INCB054329 Monotherapy - 20 mg BID (n=14): 2130 (1690); INCB054329 Monotherapy - 22.5 mg BID (n=12): 1970 (1560); INCB054329 Monotherapy - 25 mg BID (n=8): 995 (843); INCB054329 Monotherapy - Overall Dosing Regimen (n=51): NA (NA) [Dose dependent parameter and overall summary not provided.].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Cl/F Analysis of INCB054329 [Summary of steady-state PK parameters by dosing regimen at Day 15]. Mean, L/h (Standard Deviation). INCB054329 Monotherapy - 15 mg QD (n=4): 61.8 (21.3); INCB054329 Monotherapy - 15 mg BID (n=4): 85.0 (42.9); INCB054329 Monotherapy - 22.5 mg BID (n=4): 81.7 (29.4); INCB054329 Monotherapy - 30 mg QD (n=4): 234 (184); INCB054329 Monotherapy - 20 mg BID (n=14): 92.3 (201); INCB054329 Monotherapy - 22.5 mg QD (n=11): 48.3 (33.7); INCB054329 Monotherapy - 25 mg BID (n=7): 130 (127); INCB054329 Monotherapy - Overall Dosing Regimen (n=48): 95.5 (135).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Pharmacodynamics (PD) Analysis - Total c-Myc % Inhibition Versus INCB054329 [Day 15 in all cohorts]. Number, nM. INCB054329 Monotherapy (n=49): 283.4.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Objective Response Rate (ORR) [Baseline through end of study, up to 6 months]. Count Of Participants, Participants. Complete response (CR): Part 2 / Treatment Group A: 20 MG BID INCB054329 (n=10): 0. Partial response (PR): Part 2 / Treatment Group A: 20 MG BID INCB054329 (n=10): 0. Stable disease (SD) >= 6 months: Part 2 / Treatment Group A: 20 MG BID INCB054329 (n=10): 0. Stable disease (SD) < 6 months: Part 2 / Treatment Group A: 20 MG BID INCB054329 (n=10): 4. Progressive disease (PD): Part 2 / Treatment Group A: 20 MG BID INCB054329 (n=10): 5. Not evaluable (NE): Part 2 / Treatment Group A: 20 MG BID INCB054329 (n=10): 1.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Duration of Response (DOR) [Baseline through end of study, up to 6 months].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Progression Free Survival (PFS) [Baseline through end of study, up to 6 months]. Median, months (95% Confidence Interval). Part 2 / Treatment Group A: 20 MG BID INCB054329 (n=10): 2.04 (0.63 to 4.21).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Survival (OS) [Baseline through end of study, up to 6 months for participants in Part 2]. Median, months (95% Confidence Interval). Part 2 / Treatment Group A: 20 MG BID INCB054329 (n=10): 7.09 (3.13 to NA) [The upper CI limit of median PFS could not be estimated by the Brookmeyer and Crowley method because there were not enough events.].